Mukit Fabliha A, Manley Andrew, Patel Akash B, Hashemi Marium, Laplant Jacquelyn F, Fleming James C, Fowler Brian T
Ophthalmology, Hamilton Eye Institute, Memphis, USA.
Ophthalmology, The University of Tennessee Health Science Center, Memphis, USA.
Cureus. 2024 Apr 19;16(4):e58585. doi: 10.7759/cureus.58585. eCollection 2024 Apr.
As the use of teprotumumab for thyroid eye disease (TED) becomes more prolific, there remains a scarcity of literature regarding the associated side effects and adverse events of teprotumumab use. The authors present a single-center retrospective, observational case review of TED patients who received at least a single dose of teprotumumab infusion at the oculofacial plastic surgery service between February 2020 and July 2023. The most predominant recollected side effects were fatigue, brittle nails, dry eye symptoms, hair loss, muscle spasms, and dry mouth. Significant adverse events were limited to two cases of a blood clot and a single case of pulmonary embolism. This is the first retrospective study of patient-reported side effects and adverse events experienced by a cohort of teprotumumab users.
随着替普罗单抗用于治疗甲状腺眼病（TED）的情况越来越普遍，关于使用替普罗单抗的相关副作用和不良事件的文献仍然匮乏。作者对2020年2月至2023年7月期间在眼面部整形手术科室接受至少单剂量替普罗单抗输注的TED患者进行了一项单中心回顾性观察病例分析。最常见的副作用是疲劳、指甲变脆、干眼症状、脱发、肌肉痉挛和口干。严重不良事件仅限于两例血栓和一例肺栓塞。这是第一项关于一组替普罗单抗使用者报告的副作用和不良事件的回顾性研究。
